3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Recurrence
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma
1
Interventions
10-propargyl-10-deazaaminopterin
12
Cyclophosphamide
8
Prednisone
7
belinostat
6
Vincristine
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Doxorubicin
6
Brentuximab Vedotin
5
romidepsin
4
mogamulizumab
4
darinaparsin
4
Vitamin B 12
4
Gemcitabine
4
Folic Acid
4
selinexor
3
denileukin diftitox
3
Nivolumab
3
Injections
3
Bendamustine Hydrochloride
3
tislelizumab
2
tipifarnib
2
tenalisib
2
duvelisib
2
Rituximab
2
Lenalidomide
2
HBI-8000
2
Fenretinide
2
E7777 fusion protein
2
AFM13
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell, Peripheral
×
Ice
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled